© 1996 American Heart Association, Inc.
Articles |
Ultrastructural Studies of Platelet Aggregates From Human Subjects Receiving Clopidogrel and From a Patient With an Inherited Defect of an ADP-Dependent Pathway of Platelet Activation
the UMR 5533 CNRS, Hopital Cardiologique, Pessac, France; Sanofi Recherche, Toulouse, France (P.S., J-M.H.); and the Department of Vascular Biology, Scripps Research Institute, La Jolla, Calif (T.J.K.).
Correspondence to Alan T. Nurden, Director, UMR 5533 CNRS, Hopital Cardiologique, 33604 Pessac, France.
Our study investigated the effect of the antithrombotic drug clopidogrel (75 mg/d for 7 days) on the ultrastructure of platelet aggregates induced by ADP or 2-methylthio-ADP (2-MeS-ADP) in citrated platelet-rich plasma and examined the activation state of the GP IIb/IIIa complexes. Results were compared with those obtained for patient M.L., who has a congenital disorder characterized by a reduced and reversible platelet response to ADP. When untreated normal platelets were stimulated with high-dose ADP, electron microscopy revealed large and stable aggregates often surrounded by a layer of what appeared to be degranulated platelets. The reversible aggregates of platelets from subjects receiving clopidogrel or from patient M.L. did not show this layer. Electron microscopy showed that in both situations, the aggregates were composed of loosely bound platelets with few contact points. Immunogold labeling of ultrathin sections of Lowicryl-embedded aggregates formed by ADP or 2-MeS-ADP showed a much decreased platelet surface staining by (1) a polyclonal anti-fibrinogen antibody and (2) AP-6, a murine anti–ligand-induced binding site monoclonal antibody specific for GP IIb/IIIa complexes occupied with fibrinogen. Similar findings were seen after disaggregation, when many single platelets were present that showed no signs of secretion. Flow cytometry confirmed that the number of ligand-occupied GP IIb/IIIa complexes was much lower on platelets stimulated with ADP or 2-MeS-ADP after clopidogrel treatment. As expected from previous studies, ADP-induced platelet shape change and Ca2+ influx were unaffected by clopidogrel. These results agree with the hypothesis that platelet activation by ADP is biphasic and highlight a receptor-induced activation pathway affected by clopidogrel (or congenitally impaired in patient M.L.) that is necessary for the full activation of GP IIb/IIIa and the formation of stable macroaggregates.
Key Words: platelet aggregation • ADP • fibrinogen • GP IIb/IIIa complexes • clopidogrel
This article has been cited by other articles:
 |
|
 |
|
  M. R. BAKHRU and D. L. BHATT INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin? Cleveland Clinic Journal of Medicine, April 1, 2008; 75(4): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Brass, L. Zhu, and T. J. Stalker Novel Therapeutic Targets at the Platelet Vascular Interface Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s43 - s50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Nurden and P. Nurden Advantages of Fast-Acting ADP Receptor Blockade in Ischemic Heart Disease Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 158 - 159. [Full Text] [PDF]
|
|
|
|
|
|
K. Wang, X. Zhou, Z. Zhou, K. Tarakji, M. Carneiro, M. S. Penn, D. Murray, A. Klein, R. G. Humphries, J. Turner, et al. Blockade of the Platelet P2Y12 Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 357 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Remijn, Y.-P. Wu, E. H. Jeninga, M. J.W. IJsseldijk, G. van Willigen, P. G. de Groot, J. J. Sixma, A. T. Nurden, and P. Nurden Role of ADP Receptor P2Y12 in Platelet Adhesion and Thrombus Formation in Flowing Blood Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 686 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reist, M. R.-d. Vos, J.-P. Montseny, J. M. Mayer, P.-A. Carrupt, Y. Berger, and B. Testa Very Slow Chiral Inversion of Clopidogrel in Rats: A Pharmacokinetic and Mechanistic Investigation Drug Metab. Dispos., April 13, 2001; 28(12): 1405 - 1410. [Abstract] [Full Text]
|
|
|
|
|
|
M. Cattaneo and C. Gachet ADP Receptors and Clinical Bleeding Disorders Arterioscler Thromb Vasc Biol, October 1, 1999; 19(10): 2281 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Geiger, J. Brich, P. Honig-Liedl, M. Eigenthaler, P. Schanzenbacher, J. M. Herbert, and U. Walter Specific Impairment of Human Platelet P2YAC ADP Receptor–Mediated Signaling by the Antiplatelet Drug Clopidogrel Arterioscler Thromb Vasc Biol, August 1, 1999; 19(8): 2007 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nurden, C. Poujol, C. Durrieu-Jais, J. Winckler, R. Combrie, L. Macchi, C. Bihour, C. Wagner, R. Jordan, and A. T. Nurden Labeling of the Internal Pool of GP IIb-IIIa in Platelets by c7E3 Fab Fragments (abciximab): Flow and Endocytic Mechanisms Contribute to the Transport Blood, March 1, 1999; 93(5): 1622 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bihour, C. Durrieu-Jais, L. Macchi, C. Poujol, P. Coste, P. Besse, P. Nurden, and A. T. Nurden Expression of Markers of Platelet Activation and the Interpatient Variation in Response to Abciximab Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 212 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Steinhubl, M. S. Lauer, D. P. Mukherjee, D. J. Moliterno, A. M. Lincoff, S. G. Ellis, and E. J. Topol The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1366 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schror Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel Vascular Medicine, August 1, 1998; 3(3): 247 - 251. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Remijn, Y.-P. Wu, E. H. Jeninga, M. J.W. IJsseldijk, G. van Willigen, P. G. de Groot, J. J. Sixma, A. T. Nurden, and P. Nurden Role of ADP Receptor P2Y12 in Platelet Adhesion and Thrombus Formation in Flowing Blood Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 686 - 691. [Abstract] [Full Text] [PDF]
|
|